INDICATORS OF AMINO ACIDS AGAINST THE BACKGROUND OF TAKING BISPHOSPHONATE GROUP DRUGS IN PATIENTS WITH INFLAMMATORY DISEASES OF THE MAXILLOFACIAL REGION
DOI:
https://doi.org/10.54890/.v2i2.318Abstract
Summary. The paper presents the results of the effect of intravenous administration of
bisphosphonates on the structure of renal units. Patients with bisphosphonate osteonecrosis have a
predisposition to oxidative stress, revealed by calculating the ratio between reduced glutathione
(GSH) and oxidized glutathione (GSSG), which leads to a decrease in the content of molecules such
as lipids, proteins and amino acids.
Keywords:
bisphosphonate-related osteonecrosis of the jaw, amino acids, nephrotoxicity, bisphosphonates; intravenous administration; zoledronic acid; zoledronate; ibandronate.References
1. Roger MJ, Gordon S, Benford HL, et al. “Cellular and molecular mechanisms of action ofbisphosphonates,” pp. 2961–2978, 2000.
2. Tanvetyanon T, Stiff P.J. “Management of the adverse effects associated with intravenous bisphosphonates,” pp. 897–907, Ann Oncol 2006.
3. TetsuhiroYoshinami, Toshinari Yagi, Daisuke Sakai, Naotoshi Sugimoto, Fumio Imamura “A Case of Acquired Fanconi Syndrome Induced by Zoledronic Acid,” pp.
-1078, 2011.
4. Naoto Miura, Natsuko Mizuno, Ryuhei Aoyama, Wataru Kitagawa, Harutaka Yamada, Kazuhiro Nishikawa, Hirokazu Imai, “Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis,” https://link.springer.com/article/10.1007/s1015
-008-0078-x, 2009.
5. Dileep Sharma, SasoIvanovski, Mark Slevin, Stephen Hamlet, Tudor S Pop, KlaraBrinzaniuc, Eugen B. Petcu, Rodica I Miroiu, “Bisphosphonate-related osteonecrosis
of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpectedanti-angiogenic side effect,” https://www.ncbi.nlm.nih.gov/pmc/articles/PM
C3606312/, 2013.
6. Yuka Nakaya, Mayu Takaya, YutaHinatsu, TammamAlama, KosukeKusamori, Hidemasa Katsumi, ToshiyasuSakane, Akira Yamamoto, “Enhanced Oral Delivery of Bisphosphonate by Novel Absorption Enhancers: Improvement of Intestinal Absorption of Alendronate by N-Acyl Amino Acids and N-Acyl Taurates and Their
Absorption-Enhancing Mechanisms,” pp. 1-10, 2016.
7. Martha A. Sánchez-Rodríguez and Víctor Manuel Mendoza-Núñez, “Oxidative Stress Indexes for Diagnosis of Health or Disease in Humans,” pp. 13, 17, 2019.
8. Jose Bagan, Guillermo T. Saez, M. Carmen Tormos, Carmen Gavalda-Esteve, Leticia Bagan, Manuel Leopoldo-Rodado, Javier Calvo, Carlos Camps, “Oxidative stress
in bisphosphonate-related osteonecrosis of the jaws,” pp. 372-374, 2014.
9. Karabulut A.B., Gül M, Karabulut E., Kiran T.R., Ocak S.G., Otlu O., “Oxidant and antioxidant activity in rabbit livers treated with zoledronic acid,” pp. 3820–3822, Transplant Proc 2010.
10. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. “Collapsing focal segmental glomerulosclerosis following treatment with high-dose
pamidronate,” pp. 1164–1172, J Am Soc Nephrol 2001.
Downloads
Published
How to Cite
Issue
Section
